世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

会員登録

マイページ

高コレステロール血症 - パイプラインレビュー 2017年下半期

Hypercholesterolemia - Pipeline Review, H2 2017

 

出版社 出版年月電子媒体価格ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2017年11月US$2,000
シングルユーザライセンス
209

サマリー

Hypercholesterolemia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2017, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 3, 1, 20, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



目次

Table of Contents

Table of Contents
Table of Contents 2
Introduction 5
Hypercholesterolemia - Overview 6
Hypercholesterolemia - Therapeutics Development 7
Hypercholesterolemia - Therapeutics Assessment 19
Hypercholesterolemia - Companies Involved in Therapeutics Development 29
Hypercholesterolemia - Drug Profiles 45
Hypercholesterolemia - Dormant Projects 180
Hypercholesterolemia - Discontinued Products 184
Hypercholesterolemia - Product Development Milestones 186
Appendix 201

 

Companies Mentioned

AFFiRiS AG
Akcea Therapeutics Inc
ARMO Biosciences Inc
AstraZeneca Plc
BioLingus AG
Catabasis Pharmaceuticals Inc
Chong Kun Dang Pharmaceutical Corp
CymaBay Therapeutics Inc
Daewon Pharm Co Ltd
Daewoong Co Ltd
Dicerna Pharmaceuticals Inc
Dybly AG
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Golden Biotechnology Corp
Hanmi Pharmaceuticals Co Ltd
Immune Response BioPharma Inc
Kadmon Corp LLC
Kyorin Pharmaceutical Co Ltd
Leading BioSciences Inc
LipimetiX Development Inc
Lotus Pharmaceutical Co Ltd
Madrigal Pharmaceuticals Inc.
Medlab Clinical Ltd
Nanoform Cardiovascular Therapeutics Ltd
Noxopharm Ltd
Pfizer Inc
Progenra Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Viking Therapeutics Inc

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問い合せは、お電話・メール・WEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問い合せはこちらのフォームから承ります

office@dri.co.jp

 

ページTOPに戻る